Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.
BACKGROUND
Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally.


OBJECTIVE
To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence.


METHODS
The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group.


RESULTS
This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals.


CONCLUSIONS
These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Brozek
Jan L
JL
Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada.
Bousquet
Jean
J
Baena-Cagnani
Carlos E
CE
Bonini
Sergio
S
Canonica
G Walter
GW
Casale
Thomas B
TB
van Wijk
Roy Gerth
RG
Ohta
Ken
K
Zuberbier
Torsten
T
Schünemann
Holger J
HJ
D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic / Q000592:standards; D005260:Female; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D014028:Tobacco Smoke Pollution / Q000009:adverse effects
D014028:Tobacco Smoke Pollution